Treatment of hepatitis C with interferon and ribavirin

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue 6, 2000, Pages 581-586

  Pianko, Stephen ^a,b   McHutchison, John G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Combination therapy; Hepatitis C; Interferon; Ribavirin

Indexed keywords

INTERFERON; RIBAVIRIN;

ADULT; AGED; ANTIVIRAL ACTIVITY; DIARRHEA; DRUG EFFECT; FEMALE; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; INSOMNIA; LEUKOPENIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RELAPSE; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TERATOGENICITY; VIRUS LOAD;

EID: 0033934330     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02082.x     Document Type: Review

References (29)

1. 1 Alter MJ, Mast EE.The epidemiology of viral hepatitis in the United States. Gastroenterol. Clin. North Am. 1994; 23: 437-55.
2. 2 Seeff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group (see comments). N. Engl. J. Med. 1992; 327: 1906-11.
3. 3 Koretz R, Abbey H, Coleman E, Gitnick G. Non-A, non-B post transfusion hepatitis: looking back in the second decade. Ann. Intern. Med. 1993; 119: 110-15.
4. 4 Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev. 1996; 2: 219-28.
5. 5 Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 1986; 315: 1575-8.
6. 6 Simon DM, Gordon SC, Kaplan MM et al. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial (see comments). Hepatology 1997; 25: 445-8.
7. 7 Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology 1998; 27: 1121-7.
8. 8 Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy inchronic hepatitis C patients using viral and biochemical characteristics: A comparison. Hepatology 1997; 26: 1640-5.
9. 9 McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group (see comments). N. Engl. J. Med. 1998; 339: 1485-92.
10. 10 Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
11. 11 Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or incombination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group (see comments). N. Engl. J. Med. 1998; 339: 1493-9.
12. 12 Di Bisceglie AM, Shindo M, Fong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-54.
13. 13 Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev. Infect. Dis. 1990; 12: 1139-46.
14. 14 Dusheiko G, Main J, Thomas H et al. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study. J. Hepatol. 1996; 25: 591-8.
15. 15 Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 1995; 23: 8-12.
16. 16 Lai MY, Kao JH, Yang PM et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
17. 17 Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group (see comments). Lancet 1998; 351: 83-7.
18. 18 Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob. Agents Chemother. 1993; 37: 595-7.
19. 19 Orito E, Mizokami M, Suzuki K et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long term response in patients with chronic hepatitis C. J. Med. Virol. 1995; 46: 109-15.
20. 20 Marcellin P, Boyer N, Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy (see comments). Ann. Intern. Med. 1997; 127: 875-81.
21. 21 Shiffman ML, Hofmann CM, Thompson EB et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780-5.
22. 22 De Salvo GL, Noventa F, Chemello L, Pontisso P, Alberti A. Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. J. Viral Hepat. 1997; 4: 79-83.
23. 23 Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 1997; 26 (Suppl.1): S137S-42.
24. 24 Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou J. Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J. Infect. Dis. 1993; 167: 780-1.
25. 25 Heathcote EJL, Keeffe E, Lee SS et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998; 27: 1136-43.
26. 26 Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alpha in interferon alpha relapsers and non responders: Italian experience. J. Hepatol 1995; 23: 13-16.
27. 27 Alberti A, Chemello L, Belussi F et al. Outcome of acute hepatitis C and role of interferon alpha therapy. In: Nishioka K, Suzuki H, Oda T, eds. Viral Hepatitis and Liver Disease. Tokyo: Springer, 1994; 604-6.
28. 28 Lampertico P, Rumi M, Romeo R et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19: 19-22.
29. 29 Hoofnagle JH.Therapy of viral hepatitis. Digestion 1998; 59: 563-78.